Factors affecting 90-day mortality in community and hospital acquired pneumonia patients with or without acute kidney injury

Derya Hoşgün¹, Semih Aydemir²

1. Atatürk Chest Diseases and Chest Surgery Education and Research Hospital, Department of Intensive Care Unit, Ankara, Turkey. (Chest Disease Specialist, Intensive Care Specialist)
2. Atatürk Chest Diseases and Chest Surgery Education and Research Hospital, Department of Intensive Care Unit, Ankara, Turkey. (Anaesthesiology and Reanimation Specialist)

Author details:
Derya Hoşgün: deryahosgun@gmail.com; ORCID: 0000-0003-1221-3620; Semih Aydemir: drseminhaydemir@gmail.com; ORCID: 0000-0002-1087-3070

Abstract
Background: AKI is a significant risk factor for mortality. Inflammatory markers are commonly used in the prediction of prognosis in pneumonia patients. The present study aimed to evaluate the prevalence of AKI in hospitalized CAP and HAP patients and to investigate the role of inexpensive, practical, routinely measured serum biomarkers in predicting 90-day mortality.

Materials and Methods: The retrospective study included 381 patients in CAP patients and HAP patients who were hospitalized in our Chest Diseases clinic or ICU.

Results: Ninety-day mortality occurred in 115 (30.2%) patients (CAP, 28.7%; HAP, 34.7%). AKI was detected in 25.5% of the patients. On multivariate logistic regression analysis, the 90-day mortality risk was 0.931, 1.05, 0.607, and 1.999 times greater in patients with an increased APACHE II score and increased WBC, 1-h creatinine, and 48-h creatinine levels, respectively. In CAP patients, the 90-day mortality risk was 0.296, 0.539, and 1.966 times greater in patients with an increased CURB-65 score and elevated 1-h and 48-h creatinine levels, respectively. In HAP patients, however, the 90-day mortality risk was 3.554 times greater in patients with an increased 48-h creatinine level.

Conclusion: Novel practical scoring systems based on serum creatinine levels are needed for the prediction of long-term prognosis in pneumonia patients.

Key words: Community Acquired Pneumonia, Hospital Acquired Pneumonia, Acute Kidney Injury.

DOI: https://dx.doi.org/10.4314/ahs.v22i3.61

Cite as: Hoşgün D, Aydemir S. Factors affecting 90-day mortality in community and hospital acquired pneumonia patients with or without acute kidney injury. Afri Health Sci. 2022;22(3): 567-577. https://dx.doi.org/10.4314/ahs.v22i3.61

Introduction
Community Acquired Pneumonia (CAP) is basically defined as a pneumonia acquired in the community during daily life activities and hospital Acquired Pneumonia (HAP) is defined as a pneumonia that occurs within 48 h after hospital admission or within 48 h after discharge.¹³

Acute kidney injury (AKI) is a significant factor contributing to mortality in hospitalized pneumonia patients, particularly in patients hospitalized in intensive care unit (ICU).⁴

Pneumonias are often diagnosed based with the aid of biomarkers that are specific to the lung infection or are expressed in response to the inflammation. Although the specificity and sensitivity of these biomarkers may vary, they have high positive predictive values (PPVs) and negative predictive values (NPVs). In some studies, however, CRP has been shown to be an inadequate biomarker in the prediction of prognosis since it is elevated in the settings of stress, extrapulmonary infections, and auto-

Corresponding author:
Derya Hoşgün,
Atatürk Chest Diseases and Chest Surgery Education and Research Hospital, Department of Intensive Care Unit, Ankara, Turkey.
(Chest Disease Specialist, Intensive Care Specialist)
Tel: +903125677000, Fax: +903123552135
E-mail:deryahosgun@gmail.com

African Health Sciences, Vol 22 Issue 3, September, 2022
immunity. In contrast, another study reported that PCT is highly useful in predicting the requirement of ICU and vasopressor support. On the other hand, Neeser et al. evaluated CAP caused by Mycoplasma pneumoniae (M. pneumoniae) and reported that the CRP/PCT ratio (at a cut-off level of 400 mg/μg) could be used for the diagnosis. Recent studies have investigated the efficacy of inexpensive and routinely used biomarkers in the prediction of short- and long-term mortality and prognosis in inflammatory diseases. The studies concluded that the red blood cell distribution width (RDW) values increased despite the variation in the cut-off values and also serum albumin (ALB) levels decreased. Based on these findings, the authors suggested that these two parameters could be used in predicting mortality. In a related manner, the RDW/platelet (PLT) ratio has been found to be a prognostic factor in patients with acute pancreatitis and to be an early prognostic factor in patients with severe burn injury.

The present study was designed to evaluate the prevalence of AKI in hospitalized CAP and HAP patients and to investigate the role of inexpensive, practical, routinely measured serum biomarkers in predicting 90-day mortality.

Materials And Methods
The retrospective study included a total 381 patients comprising CAP patients and HAP patients who were hospitalized in our Chest Diseases clinic or intensive care unit (ICU) between January 2014 and April 2020. No VAP patients were included in the study. The CAP patients were diagnosed and hospitalized within 24 h after presenting to the emergency service and the HAP patients were diagnosed and hospitalized 48 h after hospital discharge. All the patients were followed up for mortality for 90 days. All the diagnostic and treatment procedures were performed in accordance with international guidelines. The study was initiated after obtaining an ethical approval.

Microbiological samples were obtained within the first 72 h of hospitalization and were evaluated by an experienced infectious diseases specialist. CAP patients were grouped based on the Confusion Urea Respiratory Rate Blood Pressure-65 (CURB-65) scoring system. All the patients underwent chest radiography within the first 24 h after the diagnosis and the electronic images showing lobar/multilobar consolidation and ground-glass opacity were retrospectively evaluated by a Chest Diseases specialist. The patients that were hospitalized in ICU were chosen among those who met the 2007 Infectious Disease Society of America (IDSA) and American Thoracic Society (ATS) criteria regarding ICU admission. In ICU patients, the Acute Physiology and Chronic Evaluation (APACHE II) score was calculated within the first 24 h of admission for the prediction of mortality and prognosis.

AKI was diagnosed based on the 2012 Kidney Disease Improving Global Outcomes (KDIGO) criteria for staging the severity of AKI (>0.3 mg/dl increase in serum creatinine level within 48 h after admission). Exclusion criteria were as follows: pregnancy, age below 18 years, presence of an active infection other than pneumonia, VAP, connective tissue disease, prior ICU hospitalization within the last three months, ongoing RRT due to chronic kidney disease (CKD), obstructive uropathy, AKI associated with contrast material and drug-related AKI, history of iron, vitamin B12, or folic acid replacement within the last three months, malignancies, and hematological diseases.

In all patients, WBC count and hemoglobin (HGB), CRP, PCT, PLT, albumin (ALB), and blood urea nitrogen (BUN) levels were measured within the first 24 h after admission and creatinine levels were measured at the 1st and 48th h after admission. Additionally, the RDW/PLT, RDW/ALB, CRP/PCT, and PCT/ALB ratios were calculated for each patient. WBC, HGB, PLT, and RDW were measured using a Mindary BC-6800 automated hematology analyzer with the photometric method and the normal reference ranges accepted for these parameters were 4.6-10.2 10^3/µL, 12-16 g/dl, 142-424 10^3/µL, and 11.6-17.2%, respectively. CRP, BUN, creatinine, and ALB levels were measured using a Beckman Coulter autoanalyzer with the turbidimetric assay and the normal reference ranges accepted for these parameters were 0.5-10.2 mg/L, 8-20 mg/dL, 0.81-1.44 mg/dL, and 3.5-7.2 mg/L. PCT levels were measured on a Siemens ADVIA Centaur XPT Immunoassay System device using the immunoassay test and a PCT level<0.5 ng/ml was accepted to indicate a low risk and a PCT level>2 ng/ml was accepted to indicate a high risk.

Statistical Analysis
Data were analyzed using SPSS 23.0 (IBM Corp. Released 2015. IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp.). Categorical variables were expressed as frequencies (n) and percentages (%) and continuous variables were expressed as mean ± standard
deviation (SD). Categorical variables were compared using Pearson’s Chi-squared test. Multivariate analysis was performed using Logistic Regression Analysis. Normal distribution of data was analyzed using Shapiro-Wilk test. In normally distributed data, Student’s t-test was used for comparing more than two variables. In nonnormally distributed data, Mann-Whitney U test was used for comparing two variables and Kruskal-Wallis test was used for comparing more than two variables. A p value of <0.05 was considered significant.

Results

The 381 patients comprised 246 (64.6%) men and 135 (35.4%) women with a mean age of 71.64±15.22 years. Ninety-day mortality occurred in 115 (30.2%) patients. Vasopressor/inotropic support was provided in 211 (55.4%) and RRT was administered in 47 (12.3%) patients (Table 1).

Table 1. Demographic and clinical characteristics

| Variables                        | Mean±SD    | Min-Max | N  |
|----------------------------------|------------|---------|----|
|                                  | 71.64±15.22| 20-97   | 381|

| Gender                          | Male       | 246     | 64.6|
|---------------------------------|------------|---------|-----|
|                                  | Female     | 135     | 35.4|
| Pneumonia type                  | CAP        | 289     | 75.9|
|                                  | HAP        | 92      | 24.1|
| Comorbidities                   | No         | 102     | 26.8|
|                                  | Yes        | 279     | 73.2|
| Comorbidity (COPD)              | No         | 228     | 59.8|
|                                  | Yes        | 153     | 40.2|
| Comorbidity (DM)                | No         | 327     | 85.8|
|                                  | Yes        | 54      | 14.2|
| Comorbidity (CAD)               | No         | 232     | 60.9|
|                                  | Yes        | 149     | 39.1|
| Comorbidity (CHF)               | No         | 271     | 71.1|
|                                  | Yes        | 110     | 28.9|
| 90-day mortality                | No         | 266     | 69.8|
|                                  | Yes        | 115     | 30.2|
| Vasopressor/inotropic support   | Dopamine + noradrenaline | 82 | 21.5|
|                                  | Dopamine   | 6       | 1.6 |
|                                  | Noradrenaline | 123   | 32.3|
|                                  | None       | 170     | 44.6|
| RRT                             | IHD        | 16      | 4.2 |
|                                  | CRTT       | 31      | 8.1 |
|                                  | None       | 334     | 87.7|
| Hospitalization setting         | ICU        | 289     | 75.9|
|                                  | Chest diseases clinic | 92 | 24.1|
| CURB-65 score (in CAP group only) | 2       | 34     | 11.7|
|                                  | 3          | 36     | 12.3|
|                                  | 4          | 138    | 47.3|
|                                  | 5          | 81     | 27.7|

SD: Standard deviation, Min: Minimum, Max: Maximum, ICU: Intensive care unit, APACHE II: Acute Physiology and Chronic Health Evaluation II, CAP: Community-acquired pneumonia, HAP: Hospital-acquired pneumonia, COPD: Chronic obstructive pulmonary disease, DM: Diabetes mellitus, CAD: Coronary artery disease, CHF: Congestive heart failure, IHD: Intermittent hemodialysis, RTT: Renal replacement therapy, CRTT: Continuous renal replacement therapy, CURB-65: Confusion Urea Respiratory Rate Blood Pressure-65
The rate of ICU hospitalization was significantly higher in HAP patients compared to CAP patients (p<0.05). No significant difference was found between the two groups with regard to gender distribution, 90-day mortality, RRT use, and APACHE II score of ICU patients (p>0.05 for all). The requirement of vasopressor/inotropic support was significantly higher in CAP patients compared to HAP patients (p<0.05) (Table 2).

Table 2. Demographic and clinical characteristics in each group

| Variables                  | CAP (n=289) | HAP (n=92) | Total (n=381) | p     |
|----------------------------|-------------|------------|---------------|-------|
| Gender                     |             |            |               |       |
| Male                       | 185 (64.0)  | 61 (66.3)  | 246 (64.6)    | 0.689 |
| Female                     | 104 (36.0)  | 31 (33.7)  | 135 (35.4)    |       |
| 90-day mortality           |             |            |               |       |
| Yes                        | 83 (28.7)   | 32 (34.8)  | 115 (30.2)    | 0.270 |
| No                         | 206 (71.3)  | 60 (65.2)  | 266 (69.8)    |       |
| Hospitalization setting    |             |            |               |       |
| ICU                        | 188 (65.1)  | 92 (100.0) | 280 (73.5)    | 0.000*|
| Chest diseases clinic      | 101 (34.9)  | 0 (0.0)    | 101 (26.5)    |       |
| Vasopressor / inotropic support |         |            |               |       |
| Dopamine + noradrenalin    | 66 (22.8)   | 16 (17.4)  | 82 (21.5)     | 0.000*|
| Dopamine                   | 6 (2.1)     | 0 (0.0)    | 6 (1.6)       |       |
| Noradrenalin               | 73 (25.3)   | 50 (54.3)  | 123 (32.3)    |       |
| None                       | 144 (49.8)  | 26 (28.3)  | 170 (44.6)    |       |
| RRT                        |             |            |               |       |
| IHD                        | 10 (3.5)    | 6 (6.5)    | 16 (4.2)      | 0.370 |
| CRTT                       | 25 (8.7)    | 6 (6.5)    | 31 (8.1)      |       |
| None                       | 254 (87.9)  | 80 (87.0)  | 334 (87.7)    |       |

| Variables                  | TKP (n=289) | HAP (n=92) | Total (n=381) | p     |
|----------------------------|-------------|------------|---------------|-------|
| Age                        | 70.84±15.86 | 74.17±12.75| 71.64±15.22   | 0.068 |
| APACHE II score (ICU)      | 26.60±6.97  | 27.88±7.41 | 27.02±7.13    | 0.162 |

SD: Standard deviation, ICU: Intensive care unit, APACHE II: Acute Physiology and Chronic Health Evaluation II, CAP: Community-acquired pneumonia, HAP: Hospital-acquired pneumonia, IHD: Intermittent hemodialysis, RTT: Renal replacement therapy, CRTT: Continuous renal replacement therapy.
The mean levels of WBC, RDW, ALB and the mean PCT/ALB ratio were significantly lower and the mean CRP level was significantly higher in CAP patients compared to HAP patients (p<0.05). Nevertheless, no significant difference was found between the two groups with regard to the mean HGB, PCT, PLT, and 48-h creatinine levels and the mean RDW/ALB, RDW/PLT, and CRP/PCT ratios (p>0.05) (Table 3).

### Table 3. Laboratory findings

| Variables                | CAP (n=289) Mean±SD | HAP (n=92) Mean±SD | Total (n=381) Mean±SD | P    |
|--------------------------|---------------------|--------------------|-----------------------|------|
| WBC (10^3/µL)            | 12.75±6.71          | 14.82±6.14         | 13.25±6.63            | 0.009*|
| HGB (g/dL)               | 12.50±2.06          | 12.09±2.54         | 12.40±2.19            | 0.119 |
| RDW (%)                  | 16.70±3.54          | 18.48±2.62         | 17.13±3.42            | 0.000*|
| CRP (mg/L)               | 69.38±89.34         | 12.07±8.74         | 55.54±81.67           | 0.000*|
| PCT (ng/ml)              | 5.69±13.15          | 7.32±20.40         | 6.12±15.38            | 0.386 |
| PLT (10^3/µL)            | 246.55±126.4        | 240.67±108.24      | 245.13±122.15         | 0.688 |
| ALB (mg/L)               | 2.91±0.58           | 3.08±0.54          | 2.95±0.58             | 0.011*|
| BUN (mg/dL)              | 43.63±41.63         | 32.83±27.12        | 41.02±38.87           | 0.020*|
| Creatinine (1-h) (mg/dL) | 1.38±1.03           | 0.97±0.56          | 1.28±0.96             | 0.000*|
| Creatinine (48-h) (mg/dL)| 1.07±0.96           | 1.01±0.53          | 1.06±0.88             | 0.548 |
| RDW/ALB ratio            | 5.98±1.79           | 6.21±1.67          | 6.04±1.76             | 0.289 |
| RDW/PLT ratio            | 0.10±0.12           | 0.10±0.09          | 0.10±0.011            | 0.864 |
| PCT/ALB ratio            | 2.26±5.37           | 2.71±7.97          | 2.37±6.15             | 0.012*|
| CRP/PCT ratio            | 32.57±10.82         | 32.42±53.41        | 24.83±95.84           | 0.547 |

SD: Standard deviation, CAP: Community-acquired pneumonia, HAP: Hospital-acquired pneumonia, WBC: White blood cells, HGB: Hemoglobin, RDW: Red blood cell distribution width, CRP: C-reactive protein, PCT: Procalcitonin, PLT: Platelet, ALB: Albumin, BUN: Blood urea nitrogen

Table 4 presents AKI, culture growth, and radiographic localization and findings of infection.

No significant difference was found between patients with and without AKI with regard to the type of pneumonia, radiographic localization and findings of the infection, WBC and RDW levels, and the RDW/ALB and CRP/PCT ratios (p>0.05 for all). However, the APACHE II score, CRP, PCT, 1-h and 48-h creatinine levels and the RDW/PLT and PCT/ALB ratios were significantly higher in patients with AKI compared to those without AKI (p<0.05 for all). On multivariate logistic regression analysis, mode of hospitalization (inpatient clinic or ICU), administration of vasopressor/inotropic support with noradrenaline, and an increased 48-h creatinine level were found to be independent risk factors for AKI. Moreover, the mean PLT and ALB levels were significantly higher in AKI patients compared to non-AKI patients (p<0.05). Ninety-day mortality was significantly higher in non-AKI patients compared to AKI patients (p<0.05). However, no significant relationship was found between 90-day mortality and microbiological culture results and the radiographic localization and findings of the infection (p>0.05). Ninety-day mortality was higher in patients receiving intermittent hemodialysis (IHD) compared to those who were not receiving IHD (p<0.05). Similarly, it was significantly higher in patients that were receiving continuous renal replacement therapy (CRRT) and did not have mortality as an outcome compared to other patients (p<0.05 for both). On multivariate logistic regression analysis, the 90-day mortality risk was
0.931, 1.05, 0.607, and 1.999 times greater in patients with an increased APACHE II score and increased WBC, 1-h creatinine, and 48-h creatinine levels, respectively. In CAP patients, the 90-day mortality risk was 0.296, 0.539, and 1.966 times greater in patients with an increased CURB-65 score and elevated 1-h and 48-h creatinine levels, respectively (Table 5).

In HAP patients, however, the 90-day mortality risk was 3.554 times greater in patients with an increased 48-h creatinine level (Table 6).

Table 4. Acute kidney injury, culture growth, and radiographic localization and findings of infection

| Variables                        | CAP (n=289) | HAP (n=92) | Total (n=381) | p*  |
|----------------------------------|-------------|------------|---------------|-----|
| AKI (KDIGO criteria)             |             |            |               |     |
| Yes                              | 69 (23.9)   | 28 (30.4)  | 97 (25.5)     | 0.208 |
| No                               | 220 (76.1)  | 64 (69.6)  | 284 (74.5)    |     |
| Culture growth                   |             |            |               |     |
| None                             | 229 (79.2)  | 0 (0.0)    | 229 (60.1)    |     |
| Pseudomonas aeruginosa           | 26 (9.0)    | 31 (33.7)  | 57 (15.0)     |     |
| Klebsiella pneumoniae            | 4 (1.4)     | 17 (18.5)  | 21 (5.5)      | 0.000* |
| Gr (-) bacilli                   | 10 (3.5)    | 23 (25.0)  | 33 (8.7)      |     |
| S. Aerus                         | 2 (0.7)     | 0 (0.0)    | 2 (0.5)       |     |
| E. coli                          | 5 (1.7)     | 0 (0.0)    | 5 (1.3)       |     |
| Influenza virus                  | 6 (2.1)     | 0 (0.0)    | 6 (1.6)       |     |
| Acinetobacter baumannii          | 7 (2.4)     | 21 (22.8)  | 28 (7.3)      |     |
| Culture growth (Total)           |             |            |               | 0.000* |
| No                               | 229 (79.2)  | 0 (0.0)    | 229 (60.1)    |     |
| Yes                              | 60 (20.8)   | 92 (100.0) | 152 (39.9)    |     |
| Radiographic localization        |             |            |               | 0.007* |
| Lobar                            | 166 (57.4)  | 38 (41.3)  | 204 (53.5)    |     |
| Multilobar                       | 123 (42.6)  | 54 (58.7)  | 177 (46.5)    |     |
| Radiographic finding             |             |            |               | 0.000* |
| Consolidation                    | 157 (54.3)  | 31 (33.7)  | 188 (49.3)    |     |
| Ground-glass opacity             | 74 (25.6)   | 11 (12.0)  | 85 (22.3)     |     |
| Consolidation + ground-glass opacity | 58 (20.1) | 50 (54.3)  | 108 (28.3)    |     |

CAP: Community-acquired pneumonia, HAP: Hospital-acquired pneumonia, AKI: Acute kidney injury, KDIGO: Kidney Disease Improving Global Outcomes, S. Aerus: Staphylococcus aureus, Gr (-): Gram-negative, E. coli: Escherichia coli
**Table 5.** Risk factors for 90-day mortality in CAP patients

| Variables                  | OR   | OR (95% CI) | p*  |
|----------------------------|------|-------------|-----|
| CURB-65 score              | 0.296| 0.174 - 0.503 | 0.000* |
| WBC (10^3/µL)              | 1.042| 0.988 - 1.099 | 0.127 |
| HGB (g/dL)                 | 0.895| 0.769 - 1.041 | 0.151 |
| RDW (%)                    | 0.943| 0.719 - 1.237 | 0.673 |
| CRP (mg/L)                 | 0.999| 0.996 - 1.002 | 0.594 |
| PCT (ng/ml)                | 0.949| 0.845 - 1.066 | 0.376 |
| PLT (10^3/µL)              | 1.000| 0.997 - 1.003 | 0.941 |
| ALB (mg/L)                 | 1.147| 0.201 - 6.558 | 0.878 |
| Creatinine (1-h) (mg/dL)   | 0.539| 0.367 - 0.790 | 0.002* |
| Creatinine (48-h) (mg/dL)  | 1.966| 1.323 - 2.922 | 0.001* |
| RDW/PLT ratio              | 0.581| 0.039 - 8.650 | 0.693 |
| RDW/ALB ratio              | 0.967| 0.472 - 1.981 | 0.926 |
| CRP/PCT ratio              | 1.000| 1.000 - 1.000 | 0.490 |
| PCT/ALB ratio              | 1.117| 0.841 - 1.484 | 0.446 |

*p<0.05

CAP: Community-acquired pneumonia, OR: Odds ratio, CI: Confidence Interval, CURB-65: Confusion Urea Respiratory Rate Blood Pressure-65, WBC: White blood cells, HGB: Hemoglobin, RDW: Red blood cell distribution width, CRP: C-reactive protein, PCT: Procalcitonin, PLT: Platelet, ALB: Albumin

**Table 6.** Risk factors for 90-day mortality in HAP patients

| Variables                  | OR   | OR (95% CI) | p*  |
|----------------------------|------|-------------|-----|
| WBC (10^3/µL)              | 1.115| 0.933 - 1.252 | 0.066 |
| HGB (g/dL)                 | 0.961| 0.762 - 1.213 | 0.741 |
| RDW (%)                    | 1.311| 0.738 - 2.330 | 0.356 |
| CRP (mg/L)                 | 0.937| 0.875 - 1.003 | 0.062 |
| PCT (ng/ml)                | 1.075| 0.781 - 1.479 | 0.658 |
| PLT (10^3/µL)              | 1.003| 0.995 - 1.011 | 0.511 |
| ALB (mg/L)                 | 0.200| 0.008 - 4.874 | 0.323 |
| Creatinine (1-h) (mg/dL)   | 1.551| 0.509 - 4.727 | 0.440 |
| Creatinine (48-h) (mg/dL)  | 3.554| 1.015 - 12.449| 0.047* |
| RDW/PLT ratio              | 4.580| 0.153 - 2.458 | 0.470 |
| RDW/ALB ratio              | 0.568| 0.137 - 2.357 | 0.436 |
| CRP/PCT ratio              | 1.007| 0.995 - 1.018 | 0.249 |
| PCT/ALB ratio              | 0.854| 0.355 - 2.051 | 0.724 |

*p<0.05

HAP: Hospital-acquired pneumonia, OR: Odds ratio, CI: Confidence Interval, WBC: White blood cells, HGB: Hemoglobin, RDW: Red blood cell distribution width, CRP: C-reactive protein, PCT: Procalcitonin, PLT: Platelet, ALB: Albumin
Discussion

The mortality rate in CAP patients has been shown to be 8.2-30% and to be 25-50% in patients requiring hospitalization. HAP is a frequently seen hospital-acquired infection, with a reported mortality rate of 25-50%. CURB-65 and the Pneumonia Severity Index (PSI) are commonly used in CAP patients, particularly in the prediction of prognosis and mortality and also in the decision-making processes related to hospitalization and ICU requirement. APACHE II score is a frequently used scoring system in the prediction of mortality and disease severity in CAP and HAP patients hospitalized in ICU. Studies have shown that the CAP patients with a CURB-65 score of ≥3 are at 22% greater risk of mortality and the pneumonia patients that are hospitalized in ICU and have an APACHE II score of >24 have a greater risk of mortality. In the present study, 90-day mortality rate was significantly higher in HAP patients (34.7%) compared to CAP patients (28.7%) (p=0.270). These rates were consistent with those reported in the literature. Recent studies have demonstrated that the mortality rates in CAP and HAP patients have become highly similar due to the fact that the microbiological agents associated with HAP have been detected in CAP patients as well and there has been a significant increase in the number of newly diagnosed pneumonia cases owing to the advancements in age-related healthcare services.

In our study, no significant difference was found between CAP and HAP patients with regard to mortality rate, which could be attributed to the increased CURB-65 scores in CAP patients (range, 4-5), the increased ICU requirement in CAP patients (65.05%), the growth of similar microbiological agents in both groups, and the exclusion of VAP patients. On the other hand, the increased CURB-65 scores in CAP patients were found to be an independent risk factor, which was found to increase the mortality risk by 0.296 times. Studies investigating the relationship between CURB-65 score and mortality have mostly focused on short-term mortality and thus there are very few studies reporting on long-term mortality. In studies evaluating CAP patients, initial disease severity, age, cardiovascular comorbidities, and inflammation have been shown to be predictive factors for long-term mortality. To our knowledge, this study is one of the rarest studies in the literature to show the efficacy of CURB-65 score in predicting long-term mortality in CAP patients. Additionally, the study also aimed to improve this efficacy by adding inexpensive, practical, and routinely measured inflammatory biomarkers into the analysis.

The analysis revealed that the 90-day mortality risk was 0.931 times greater in patients that were hospitalized in ICU and had an increased APACHE II score. The APACHE II score is commonly used in the prediction of early in-hospital mortality in critically ill patients. In our study, the APACHE II scores were calculated only within the first 24 h of ICU admission and no additional calculations were performed, unlike in many studies in the literature. Hosseini et al. found the APACHE II score as a significant predictor of 6-month mortality in surgical and medical ICU patients. Although our study had similar outcomes with the studies in the literature regarding the role of the APACHE II score in predicting mortality in pneumonia patients, the APACHE II scores of our patients were not further analyzed by Multivariate Logistic Regression analysis due to the small numbers of ICU patients in our CAP and HAP groups.

Acute kidney injury (AKI) is defined as the sudden loss of kidney function resulting in the inept accumulation of waste products such as urea and nitrogenous waste products. Bagai et al. evaluated 122 patients with CAP and detected AKI in 40.2% of the patients who had a higher risk of in-hospital mortality. A multicentric study evaluated 11,500,546 pneumonia hospitalizations and reported that RRT was administered in 4.3% and AKI-related mortality occurred in 32.4% of the patients. Another study evaluated sepsis patients and detected AKI in more than 50% of the patients. In the present study, a diagnosis of AKI was established based on KDIGO criteria and AKI was diagnosed in 25.5% of the patients, which was consistent with those reported in the studies investigating CAP and HAP patients. Moreover, RRT was administered in 12.3% of our AKI patients.

Literature indicates that RRT is used in 12-25% of sepsis patients. Accordingly, the rate of RRT use in our study was consistent with those reported in the literature. Contrariwise, no significant relationship was found between RRT use and AKI (p=0.370 and p=0.208, respectively), which could be explained by the fact that both CAP and HAP patients had severe pneumonia and had increased requirement of vasopressor/inotropic support and all the AKI patients were hospitalized in ICU. Due to the retrospective nature of our study, no data regarding the factors associated with RRT such as body mass index (BMI), early or late initiation of RRT, administration of CRRT, and the dosing and duration of IDH could be attained and thus no standardization could be performed.
in the study.\textsuperscript{20,21} This limitation could be associated with the higher mortality rate in our non-AKI patients. In line with the literature, mode of hospitalization (inpatient clinic or ICU), administration of vasopressor/inotropic support with noradrenaline, and an increased 48-h creatinine level were found to be independent risk factors for AKI (p<0.05 for all).\textsuperscript{16} In kidney function tests, BUN levels typically increase in the setting of dehydration, and serum creatinine level is affected not only by kidney dysfunction but also by age, gender, nutritional status, liver disease, and fluid volume status.\textsuperscript{20} Cho et al. found that increased creatinine levels were a useful predictor of short-term mortality in patients with sepsis-induced AKI that were receiving RRT.\textsuperscript{22} In our study, serum BUN levels were significantly higher in CAP patients compared to HAP patients, which could be associated with the higher prevalence of dehydration findings and the community origin of the infection in CAP patients.\textsuperscript{20} Moreover, the higher BUN levels in CAP patients were found to result in higher 1-h creatinine levels in these patients compared to those in HAP patients. In our study, the 1-h and 48-h creatinine levels in CAP patients, as consistent with the literature, were found to be significant predictors of mortality.\textsuperscript{21} In contrast, only the 48-h creatinine level was found to be a significant predictor of mortality in HAP patients, which could be attributed to the hospital origin of the infection, the lower prevalence of dehydration findings in CAP patients, and the exacerbation of the disease within the first 72 h of hospitalization. Our study had a limitation regarding the creatinine levels. Due to the retrospective nature of our study, no data regarding patients’ nutritional status, BMI, and fluid volume status could be attained and thus no standardization could be performed for the medical therapies performed in the study.

A previous study evaluated pneumonia patients that were hospitalized in the clinic or ICU and reported that serial measurement of CRP and PCT levels within the first 72 h of hospitalization was highly useful in predicting treatment response, prognosis, and mortality.\textsuperscript{23} Albumin is secreted from liver cells in response to oxidative stress in the setting of inflammation and has been shown to be a prognostic factor in predicting mortality in pneumonia patients.\textsuperscript{23,24} RDW, WBC, and PLT are routinely measured blood parameters that have been shown to increase or decrease in the setting of infection.\textsuperscript{26} Recent studies have investigated the diagnostic role of the ratios of these parameters to one another due to the fact that these parameters have been shown to increase or decrease in the setting of inflammation and their specificity and sensitivity levels are different from one another. A previous study evaluated CAP caused by M. pneumoniae and reported that the increased CRP/PCT ratio calculated on admission could have a diagnostic value.\textsuperscript{7,9} Luo et al. evaluated 140 patients with urosepsis and demonstrated that the PCT/ALB ratio could be useful in the early diagnosis and clinical practice.\textsuperscript{27} Yoo et al. reported that the RDW/ALB ratio provided better outcomes in predicting 60-day mortality compared to RDW alone in patients with acute respiratory distress syndrome (ARDS).\textsuperscript{28} In a previous retrospective study, Wang et al. evaluated children with sepsis and reported that the RDW/PLT ratio calculated on admission was closely associated with the prognosis.\textsuperscript{29,30} In our study, the WBC, RDW, ALB levels and the PCT/ALB ratio were significantly lower and the CRP level was significantly higher in CAP patients compared to HAP patients, and ALB, CRP, and the PCT/ALB ratio were found to be predictors of disease severity in CAP.\textsuperscript{21} Moreover, CAP and HAP patients had similar mortality rates and the CAP patients that received outpatient care and VAP patients were excluded from the study, which could have affected the laboratory findings obtained in the study. On the other hand, the RDW/PLT, RDW/ALB, CRP/PCT, and PCT/ALB ratios, which have been investigated in recent studies, had no significant effect in the prediction of 90-day mortality. Similarly, serum creatinine level had no significant effect in the prediction of 90-day mortality, which could be associated with the high rates of AKI and RRT use in our patients, which are indicators of disease severity.

**Conclusion**

The results implicated that there is need for novel scoring systems similar to CURB-65 score, which is used for CAP patients, for the prediction of prognosis and disease severity in HAP patients.\textsuperscript{4} Additionally, to evaluate the role of CURB-65 in predicting long-term mortality in CAP patients, novel scoring systems that are based on serum creatinine levels rather than serum BUN levels are needed. Further multicentric prospective studies performing repeated measurements of routinely measured inflammatory biomarkers are needed to investigate the role of these biomarkers in the prediction of disease severity and prognosis in pneumonia patients.
Ethics approval
Atatürk Chest Diseases and Surgery Training and Research Hospital, ethics committee (Date number: 06/11/2020, number: 677)

References
1- Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/Ameriaca Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44:S27-S72; doi: 10.1086/511159.
2- Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guideline by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63:e61-e111; doi: 10.1097/cid/ciw353.
3- Ferreira-Coimbra J, Tejada S, Campogiani L, Rello J. Levels of evidence supporting European and American community-acquired pneumonia guidelines. Eur J Clin Microbiol Infect Dis. 2020;39(6):1159-1167; doi: 10.1007/s10096-020-03833-8.
4- Wan L, Bagshaw SM, Langenberg C, Saotome T, May CB, Bellomo R. Pathophysiology of Septic Acute Kidney Injury: What Do We Really Know? Crit Care Med 2008;36(4):198-203; doi: 10.1097/CCM.0b013e318168cd5.
5- Farah R, Khamisy-Farah R, Makhoul N. Consecutive Measures of CRP Correlate with Length of Hospital Stay in Patients with Community-Acquired Pneumonia. Isr Med Assoc J 2018;20(6):345-348.
6- Guo S, Mao X, Liang M. The moderate predictive value of serial serum CRP and PCT levels fort he prognosis of hospitalized community-acquired pneumonia. Respir Res 2018;19(1):193; doi: 10.1186/s12931-018-0877-x.
7- Neeser OL, Vukajilovic T, Felder L, et al. A high C-reactive protein/procalcitonin ratio predicts Mycoplasma pneumoniae infection. Clin Chem Lab Med. 2019;57(10):1638-1646; doi: 10.1515/cclm-2019-0194.
8- Han YQ, Zhang L, Yan L, Li P, Ouyang PH, Lippi G, Hu ZD. Red blood cell distribution width predicts long-term outcomes in sepsis patients admitted to the intensive care unit. Clin Chim Acta 2018;487:112-116; doi: 10.1016/j.cca.2018.09.019.
9- Cetinkaya E, Senol K, Saylam B, Tez M. Red cell distribution width to platelet ratio: a new and promising prognostic marker in acute pancreatitis. World J Gastroenterol 2014;20(39):14450-14454; doi: 10.3748/wjg.v20.i39.14450.
10- Varghese YE, Kalaiselvan MS, Renuka MK, Arunkumar AS. Comparison of acute physiology and chronic health evaluation II (APACHE II) and acute physiology and chronic health evaluation IV (APACHE IV) severity of illness scoring systems, in a multidisciplinary ICU. J Anaesthesiol Clin Pharmacol 2017;33(2):248-253; doi: 10.4103/0970-9185.209741.
11- Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 2013;17(1):204; doi: 10.1186/cc11454.
12- Ferreira-Coimbra J, Sarda C, Rello J. Burden of Community-Acquired Pneumonia and Unmet Clinical Needs. Adv Ther 2020;37(4):1302-1318; doi: 10.1007/s12325-020-01248-7.
13- Shi Y, Huang Y, Zhang TT, et al. Chinese guidelines fort he diagnosis and treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults (2018 Edition). J Thorac Dis 2019;11(6):2581-261; doi: 10.21037/jtd.2019.06.09.
14- Cavallazzi R, Furmanek S, Arnold FW, et al. The Burden of Community-Acquired Pneumonia Requiring Admission to an Intensive Care Unit in the United States. Chest 2020;S0012-3692(20)30676-0; doi: 10.1016/j.chest.2020.03.051.
15- Restrepo MI, Faverio P, Anzueto A. Long-term prognosis in community-acquired pneumonia. Curr Opin Infect Dis 2013;26:151-58 PubMed, doi:10.1096/QCO.0b0113e32835ebc6d.
16- Hosseini M, Ramazani J. Evaluation of Acute Physiology and Chronic Health Evaluation II and sequential organ failure assessment scoring systems for prognostication of outcomes among Intensive Care Unit’s patients. Saudi J Anaesth 2016;10(2):168-173; doi: 10.4103/1658-354X.168817.
17- Vikrant S, Gupta D, Singh M. Epidemiology and outcome of acute kidney injury from a tertiary care hospital in India. Saudi J Kidney Dis Transpl 2018;29(4):956-966; doi: 10.4103/1319-2442.239633.
18- Bagai S, Prakash A, Agrawal A. Profile of Community-Acquired Acute Kidney Injury Definid Using RIFLE Criteria Among Medical In-Patients: A Prospective Descriptive Single Centre Study. J Assoc Physicians India 2019;67(1):14-18.
19- Mansuri U, Patel AA, Dave M, Chauhan K, Shah SA, Banala R. Impact of Dialysis Requirement in Community-acquired Pneumonia Hospitalizations. Cureus 2018;10(8):e3164.
20- Poston JT, Koyner JL. Sepsis associated acute kidney injury. *BMJ* 2019;364:k4891; doi: 10.7759/cureus.3164.

21- Nussbag C, Weigand MA, Zeier M, Morath C, Brenner T. Issues of Acute Kidney Injury Staging and Management in Sepsis and Critical Illness: A Narrative Review. *Int J Mol Sci* 2017;18(7):1387; doi: 10.3390/ijms18071387.

22- Cho AY, Yoon HJ, Lee KY, Sun IO. Clinical characteristics of sepsis-induced acute kidney injury in patients undergoing continuous renal replacement therapy. *Ren Fail* 2018;40(1):403-409; doi: 10.1080/0886022X.2018.1489288.

23- Mendez R, Aldas I, Menendez R. Biomarkers in Community-Acquired Pneumonia (Cardiac and Non-Cardiac). *J Clin Med* 2020 Feb 18;9(2);doi: 10.3390/jcm9020549.

24- Holter JC, Ueland T, Jenum PA, et al. Risk Factors for Long-Term Mortality after Hospitalized for Community-Acquired Pneumonia: A 5-Year Prospective Follow-Up Study. *PLoS One* 2016;11:e0148741; doi: 10.1371/journal.pone.0148741.

25- Hoste EA, Dhondt A. Clinical review: use of renal replacement therapies in special groups of ICU patients. *Crit Care* 2012;16(1):201; doi: 10.1186/cc10499.

26- Han YQ, Zhang L, Yan L, Li P, et al. Red blood cell distribution width predicts long-term outcomes in sepsis patients admitted to the intensive care unit. *Clin Chim Acta* 2018;487:112-116; doi: 10.1016/j.cca.2018.09.019.

27- Luo X, Yang X, Li J, et al. The procalcitonin/albulmin ratio as an early diagnostic predictor in discriminating urosepsis from patients with febrile urinary tract infection. *Medicine (Baltimore)*. 2018;97(28):e11078; doi: 10.1097/MD.0000000000011078.

28- Yoo JW, Ju S, Lee SJ, Cho YJ, Lee JD, Kim HC. Red cell distribution width/albulmin ratio is associated with 60-day mortality in patients with acute respiratory distress syndrome. *Infect Dis (Lond)* 2020;52(4):266-270; doi: 10.1080/23744235.2020.1717599.

29- Wang L, Cai Q. Value or red blood cell distribution width-to-platelet count ratio in predicting the prognosis of children with sepsis. *Zhongguo Dang Dai ErKe ZaZhi* 2019;21(11):1079-1083; doi: 10.7499/j.isssn.1008-8830.2019.11.005.

30- Çetinkaya E, Şenol K, Saylam B, Tez M. Red cell distribution width to platelet ratio: New and promising prognostic marker in acute pancreatitis. *World J Gastroenterol* 2014;20(39):14450-14454; doi: 10.3748/wjg.v20.i39.14450.